According to a recent LinkedIn post from Astraveus, the company recently hosted CELLforCURE by Seqens for an on-site visit and working session focused on cell therapy manufacturing. The post highlights that the visit included a demonstration of Astraveus’s Lakhesys™ platform and discussions around current bottlenecks and emerging trends in industrialized cell therapy processes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post describes CELLforCURE by Seqens as a leading European CDMO specializing in GMP manufacturing of advanced therapy medicinal products, supporting biotech and pharma clients from clinical to commercial stages. By engaging in hands-on technical discussions with an experienced manufacturing and analytical partner, Astraveus appears to be stress-testing its product roadmap against real-world constraints.
For investors, the interaction suggests Astraveus is positioning Lakhesys™ to align with CDMO and pharma requirements across the ATMP value chain. If such collaborations deepen into formal development or commercial agreements, they could enhance validation of the technology, support future revenue generation, and strengthen the company’s role within the European cell and gene therapy manufacturing ecosystem.